Leo Pharma achieves French milestone
Denmark-based Leo Pharma has won approval from French medicines authorities of a new indication for one of the company’s biggest products . The Danes expect additional markets to follow suit in the wake of planned studies.
by Stefan Singh Kailay
For years, Innohep has been the cornerstone of Leo Pharma’s product portfolio and, although skin diseases is the professed main area of the company, the size of the product has helped create a sizeable business in the anticoagulant area, to which Innohep belongs, says EVP of Global Sales & Marketing, Lars Olsen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
